Sentinel node surgery sufficient to detect residual breast cancer

Share this content:

Sentinel lymph node (SLN) surgery successfully identified the presence of residual breast cancer in lymph nodes in nearly all patients in a recent study. The SLN approach is less invasive than axillary lymph node dissection.

The 756 women studied all had node-positive breast cancer and had undergone chemotherapy as an initial treatment. A total of 637 had both SLN and axillary lymph node surgery. SLN surgery correctly identified the remaining presence of cancer in 91% of the women, including 255 with node-negative breast cancer and 326 with continuing node-positive disease.

As lead investigator Judy C. Boughey, MD, a breast surgeon at the Mayo Clinic in Rochester, Minnesota, noted in a statement issued by the Mayo Clinic, removing only a few lymph nodes reduces the risk of numbness, arm swelling, and other complications. The findings were presented at the CTRC-AACR San Antonio Breast Symposium held in San Antonio, Texas, December 4-8, 2012.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs